ARVO Key Abstracts:
- Tue, May 07 8:30am -
10:15am PT ;Tedi Begaj , MD;Lisa Faia , MD
CALM: 24-Month Safety Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Poster A0170)
Thu, May 09 2:30pm - 2:45pm PT ;Phoebe Lin , MD
CALM: 24-Month Retinal Thickness Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Abstract #6454)
RWC Key Abstract:
- Poster-on-demand,
Michael Singer , MD
36-month Outcomes Following Treatment of Chronic Non-infectious Uveitis Affecting the Posterior Segment with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant: a CALM Registry Analysis
About YUTIQ
YUTIQ is a sustained release fluocinolone acetonide intravitreal implant injected into the back of the eye using CONTINUOUS MICRODOSING™ technology, which is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease and enable patients to maintain vision longer with fewer injections. YUTIQ helps provide CONTINUOUS CALM™ by reducing recurrence of inflammation in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. For more information, please visit www.YUTIQ.com
About
For press inquiries: Cassy Dump for 619-971-1887 cassy@heyshine.com | For investor inquiries: for scottg@coreir.com |
Source:
2024 GlobeNewswire, Inc., source